Skip to main content

HB 216 — Hawaii

RELATING TO PRESCRIPTION DRUGS.

Introduced 2026 session House

This page lists STATE bills only. Open States, our source for this data, tracks state legislatures -- it has no visibility into city councils, county commissions or school boards. We don't yet have a free, storable source for local measures; see the About page for why.

Summary

Establishes requirements for the clinical review criteria and clinical practical guidelines used to establish step therapy protocols. Provides a process for a patient to request an exception to using step therapy protocols. Establishes insurance coverage requirements relating to the use of step therapy protocols and standards to appeal an adverse step therapy exception determination.

Official abstract, as published by the legislature.

  • HB 216 is a bill in the Hawaii House, 2026 session, introduced January 15, 2025.
  • Sponsored by TAKAYAMA, KILA, KITAGAWA, MATSUMOTO, PIERICK, and TAKENOUCHI, with 1 cosponsor.
  • Current status: introduced.
  • Most recent action (December 8, 2025): Carried over to 2026 Regular Session.
  • Subjects: Clinical Practice Guidelines, Clinical Review Criteria, Exceptions, Health Insurance, Prescription Drugs, Step Therapy Protocol.

Contact your legislator about this bill

Bill text & documents

Sponsors

Primary: TAKAYAMA, KILA, KITAGAWA, MATSUMOTO, PIERICK, TAKENOUCHI

Cosponsors (1): Tam

History

  1. Introduced, completed
  2. Passed House, in progress
  3. Passed Senate, not reached yet
  4. Sent to Governor, not reached yet
  5. Signed into law, not reached yet
  1. House Pending introduction.
  2. House Introduced and Pass First Reading. Milestone
  3. House Referred to HLT, CPC, FIN, referral sheet 1
  4. Legislature Carried over to 2026 Regular Session. Latest

Source: Open States. Last checked November 13, 2026. How we keep this accurate ›